Regulus Therapeutics IncNASDAQ:RGLS
- LAST PRICE1.5400
- TODAY'S CHANGE (%)-0.1000 (-6.0976%)
- Bid / Lots1.5400/ 20
- Ask / Lots1.5500/ 6
- Open / Previous Close1.6100 / 1.6400
- Day Range
- 52 Week Range
- Volume85,042
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGLS |
|---|---|---|
| 09:32 ET | 9295 | 1.6 |
| 09:33 ET | 2100 | 1.6001 |
| 09:35 ET | 2500 | 1.6001 |
| 09:37 ET | 100 | 1.61 |
| 09:39 ET | 2800 | 1.62 |
| 09:44 ET | 400 | 1.615 |
| 09:46 ET | 1200 | 1.6101 |
| 09:51 ET | 100 | 1.62 |
| 09:53 ET | 1498 | 1.61 |
| 09:55 ET | 599 | 1.6244 |
| 10:02 ET | 500 | 1.62 |
| 10:04 ET | 710 | 1.6 |
| 10:06 ET | 879 | 1.6 |
| 10:09 ET | 2113 | 1.595 |
| 10:11 ET | 1717 | 1.5994 |
| 10:13 ET | 1314 | 1.595 |
| 10:15 ET | 37027 | 1.58 |
| 10:18 ET | 2141 | 1.57 |
| 10:22 ET | 1280 | 1.56 |
| 10:26 ET | 100 | 1.57 |
| 10:27 ET | 100 | 1.565 |
| 10:29 ET | 2464 | 1.56 |
| 10:31 ET | 1000 | 1.555 |
| 10:33 ET | 100 | 1.55 |
| 10:36 ET | 1100 | 1.555 |
| 10:40 ET | 635 | 1.555 |
| 10:42 ET | 400 | 1.555 |
| 10:45 ET | 300 | 1.55 |
| 10:47 ET | 1890 | 1.54 |
Nov 26, 2024
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 11, 2024
DJ Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 7:36AM ET on Monday Nov 11, 2024 by Dow Jones
7:36AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Regulus Therapeutics 3Q Loss/Shr 21c >RGLS, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 30, 2024
DJ Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 8:32AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:32AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regulus Therapeutics Inc | 107.4M | -1.4x | --- |
Monopar Therapeutics Inc | 109.3M | -11.0x | --- |
INmune Bio Inc | 108.4M | -2.2x | --- |
Invizyne Technologies Inc | 109.5M | -21.2x | --- |
Pyxis Oncology Inc | 105.3M | -1.9x | --- |
Anixa Biosciences Inc | 106.5M | -8.5x | --- |
Company Information
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Contact Information
- Headquarters
- 4224 Campus Point Court, Suite 210SAN DIEGO, CA, United States 92121
- Phone
- 858-202-6300
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Stelios Papadopoulos
- President and Head of Research & Development
- Preston Klassen
- Chief Executive Officer, Director
- Joseph Hagan
- Chief Financial Officer
- Cris Calsada
- Senior Vice President, General Counsel
- Christopher Aker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 65.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.62 |
EPS | $-1.08 |
Book Value | $1.05 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
